首页> 外文期刊>Cancer letters >The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity
【24h】

The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity

机译:脱唾液酸糖蛋白受体通过LASS2介导的V-ATPase活性抑制作用抑制肝癌的转移

获取原文
获取原文并翻译 | 示例
           

摘要

The asialoglycoprotein receptor (ASGR), which is expressed mainly in hepatocytes, is downregulated in poorly differentiated hepatocellular carcinoma (HCC). Here we investigated the role of ASGR1 in HCC metastasis as well as the possible underlying molecular mechanisms. We found that ASGR1 was downregulated in HCC tissue compared with adjacent non-tumorous liver tissue and that lower ASGR1 expression was associated with higher TNM stage and poorer prognosis in HCC patients. ASGR1 overexpression inhibited hepatoma cell migration and invasion in vitro and in vivo, while ASGR1 knockdown had the opposite effects. Furthermore, ASGR1 interacted directly with human longevity assurance homolog 2 of yeast LAG1 (LASS2). Knockdown of LASS2 attenuated the inhibitory effects of ASGR1 on hepatoma cell migration and invasion in vitro. ASGR1 decreased V-ATPase activity in hepatoma cells, and this was reversed by LASS2 knockdown. Finally, HCC patients with low LASS2 levels had poor prognosis, while those with high ASGR1 and LASS2 levels had better prognosis. Thus, ASGR1 may act as a potential metastasis suppressor in HCC, and the combination of ASGR1 and LASS2 may help predict the prognosis of HCC patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
机译:主要在肝细胞中表达的去唾液酸糖蛋白受体(ASGR)在低分化肝细胞癌(HCC)中被下调。在这里,我们研究了ASGR1在肝癌转移中的作用以及可能的潜在分子机制。我们发现,与邻近的非肿瘤肝组织相比,HCC组织中的ASGR1被下调,而ASGR1表达的降低与HCC患者的TNM分期较高和预后较差有关。 ASGR1的过表达抑制了肝癌细胞在体内外的迁移和侵袭,而ASGR1的抑制则具有相反的作用。此外,ASGR1与酵母LAG1(LASS2)的人类寿命保证同源物2直接相互作用。敲低LASS2减弱了ASGR1对体外肝癌细胞迁移和侵袭的抑制作用。 ASGR1降低了肝癌细胞中的V-ATPase活性,这被LASS2敲低所逆转。最后,LASS2水平低的HCC患者预后较差,而ASGR1和LASS2水平高的HCC患者预后较好。因此,ASGR1可能是肝癌的潜在转移抑制因子,而ASGR1和LASS2的组合可能有助于预测HCC患者的预后。 (C)2016 Elsevier Ireland Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号